pSivida says BioSilicon may improve immune system

By Elaine Rigoli

Tampa, Fla., July 5 -pSivida Ltd. said Wednesday that its drug-delivery platform, BioSilicon, has demonstrated the capability to act as an adjuvant when delivered with an antigen.

The company said a patent application has been filed in the United Kingdom that covers the application of BioSilicon as an adjuvant, or any substance capable of enhancing a host response toward an active agent, often used in conjunction with antigens to enhance the immune response of humans and animals.

Recent in-vivo preclinical data demonstrate that BioSilicon alone does not stimulate the immune system, according to a news release.

The company said this finding is critical since it confirms the biocompatible attribute of this novel biodegradable biomaterial.

The controlled study also demonstrated that certain forms of BioSilicon, delivered in specific combinations with specific antigens, show an adjuvant activity equivalent to the well-established and widely used adjuvant, alum (aluminum salts).

The proprietary BioSilicon-antigen combinations resulted in an enhanced immune response based on in-vivo antibody responses, the release said.

pSivida is a global bio-nanotech company based in Perth, Australia.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.